Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report sent to investors on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Stock Up 4.1 %

Shares of NASDAQ:PULM opened at $6.29 on Tuesday. The company has a market cap of $22.97 million, a PE ratio of -2.38 and a beta of 0.99. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $8.44. The firm has a 50-day simple moving average of $2.73 and a 200 day simple moving average of $2.27.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.